CoChat

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index; 9 of the 41 sources its claims cite were checked for support.

An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species

Open access

Abstract

Recombinant adeno-associated viruses (rAAVs) have emerged as promising gene therapy vectors due to their proven efficacy and safety in clinical applications. In non-human primates (NHPs), rAAVs are administered via suprachoroidal injection at a higher dose. However, high doses of rAAVs tend to increase additional safety risks. Here, we present a novel AAV capsid (AAVv128), which exhibits significantly enhanced transduction efficiency for photoreceptors and retinal pigment epithelial (RPE) cells, along with a broader distribution across the layers of retinal tissues in different animal models (mice, rabbits, and NHPs) following intraocular injection. Notably, the suprachoroidal delivery of AAVv128-anti-VEGF vector completely suppresses the Grade IV lesions in a laser-induced choroidal neovascularization (CNV) NHP model for neovascular age-related macular degeneration (nAMD). Furthermore, cryo-EM analysis at 2.1 Å resolution reveals that the critical residues of AAVv128 exhibit a more robust advantage in AAV binding, the nuclear uptake and endosome escaping. Collectively, our findings highlight the potential of AAVv128 as a next generation ocular gene therapy vector, particularly using the suprachoroidal delivery route.

Overview

CoChat Summary

TL;DR

AAVv128, an AAV8-derived capsid engineered by rational design, shows enhanced retinal transduction across mice, rabbits, and non-human primates and suppresses Grade IV lesions in a laser-induced CNV NHP model when delivering anti-VEGF via suprachoroidal injection. Cryo-EM at 2.1 Å links its VP3 VIII loop changes to improved binding, cellular uptake, and nuclear entry.

Key findings

  • After intravitreal injection in mice, AAVv128 produced the highest eGFP mRNA among tested variants, 75-fold higher than AAV8 (6 × 10⁸ vg/eye, n = 3).
  • After subretinal injection in mice, AAVv128 showed 2-fold higher mean pixel intensity per area at Day 14 and 1.4-fold at Day 28, and 3.7-fold higher total pixel intensity at Day 14 and 3.2-fold at Day 28 versus AAV8; vector genome copies were 3.7-fold higher and relative eGFP copies/cell 3.9-fold higher.
  • In rabbits, AAVv128 vector genome abundance was 12.4-fold higher than AAV8 after intravitreal injection and 23.2-fold higher after suprachoroidal injection. In NHP suprachoroidal delivery, AAVv128 increased eGFP fluorescence in peripheral fundus.
  • In the laser-induced CNV NHP model, AAVv128-anti-VEGF via suprachoroidal injection yielded 0% Grade IV lesions at 35 and 49 days, versus 43.75% and 70.83% for vehicle and 31.25% and 41.67% for AAV8; retinal anti-VEGF levels were 2112 ng/g (OS) and 4056 ng/g (OD) for AAVv128 versus 39.12 ng/g and 52.8 ng/g for AAV8.
  • AAVv128 had pI 7.6930 versus AAV8 6.8590, infectivity 75.0 ± 37.5 vg/IU versus 797.7 ± 165.1 vg/IU, and a 2.1 Å cryo-EM structure showing a more positively charged VP3 VIII loop with additional hydrogen-bond interactions.

Methods

  • Rational design used AAV8 capsid as scaffold, replacing Q588–A592 or N263–T274 in VP3 VIII or VP3 VI variable regions with 18 peptides of 5–14 amino acids; vectors packaged eGFP, mCherry, or anti-VEGF cassettes flanked by AAV2 ITRs and were produced by HEK293T triple transfection.
  • Animal testing used C57BL/6J mice, New Zealand White rabbits, and cynomolgus monkeys; routes included intravitreal, subretinal, and suprachoroidal injection, with a laser-induced CNV NHP model for nAMD efficacy.
  • Main analyses included qRT-PCR/qPCR, ELISA, OCT/fundoscopy/FFA/SLO, immunofluorescence, DSF, cIEF, TCID50/qPCR infectivity, neutralizing antibody assays, AAV binding/uptake/nuclear fractionation assays, cryo-EM at 2.1 Å, and two-sided t-tests or one-way ANOVA.

Limitations

  • Stated limitations: Not stated in the paper.
  • Evident from the text: NHP anti-VEGF expression in Fig. 8a used n = 1 per group, while FFA efficacy used n = 8; some NHP transduction imaging also used n = 1.
  • Evident from the text: no human data are reported, so clinical translatability remains untested; the cryo-EM map resolved only residues 218–743, with VP1u and VP2 domains unresolved.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-024-48221-4

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 rAAV library screening via intravitreal injection in mice. a Schematic diagram of rAAV and rAAV variants components. b Three injection routes commonly used for AAV ophthalmic gene therapy. c Mice were sacrificed at D28 and eyes were harvested. The detection of eGFP mRNA expression levels in AAV8 and AAV8 variants after intravitreal injection in mice using RT-qPCR (6 × 108 vg/eye, n = 3). The color depicted represent relative mRNA expression levels from highest to lowest value (red to white, respectively). d The cell types across the retina were illuminated. e Mice were sacrificed at D28 and eyes were harvested. Coronal sections of rAAV-CBA-eGFP transduced mice retina. Immunofluorescence (IF) stained sections (Green) with antibodies against eGFP indicate the positively transduced cell type across the retina. (Scale bar: 50 μm, GCL ganglion cell layer, INL inner nuclear layer, ONL outer nuclear layer;). We conducted three repetitions for each sample, with each assay being operated independently. Source data are provided as a Source Data file.
Fig. 1 rAAV library screening via intravitreal injection in mice. a Schematic diagram of rAAV and rAAV variants components. b Three injection routes commonly used for AAV ophthalmic gene therapy. c Mice were sacrificed at D28 and eyes were harvested. The detection of eGFP mRNA expression levels in AAV8 and AAV8 variants after intravitreal injection in mice using RT-qPCR (6 × 108 vg/eye, n = 3). The color depicted represent relative mRNA expression levels from highest to lowest value (red to white, respectively). d The cell types across the retina were illuminated. e Mice were sacrificed at D28 and eyes were harvested. Coronal sections of rAAV-CBA-eGFP transduced mice retina. Immunofluorescence (IF) stained sections (Green) with antibodies against eGFP indicate the positively transduced cell type across the retina. (Scale bar: 50 μm, GCL ganglion cell layer, INL inner nuclear layer, ONL outer nuclear layer;). We conducted three repetitions for each sample, with each assay being operated independently. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Testing transduction of AAV8 and AAVv128 capsid following subretinal injections. a OCT images showing retinal blebbing formed at the site of subretinal administration. Representative animal eyes were shown at post-injection of necropsy (1 μL volume, n = 6). b Fluorescence fundoscopy of mouse eyes treated with PBS (1 μL volume, n = 6, scale bar: 500 μm). c–f Fluorescence fundoscopy of mouse eyes treated with ssAAV-CBA-eGFP vectors packaged with AAV8 (c) or AAVv128 (d) capsids (1×109 vg/eye, 1 μL volume, n = 6, scale bar: 500 μm). Mice were imaged at D14 and D28 post-injection, and each image of pixel intensity and mean pixel intensity per pixel area was quantified by using Image J (e, f). g, i Mice where sacrificed at D28 and eyes were harvested. Flat mounts of the retina were prepared and imaged by fluorescence microscopy to visualize native eGFP expression (g) and quantify by pixel intensity and mean pixel intensity per pixel area (i). Scale bar: 500 μm. h, j Mice retinal tissues were isolated and the relative eGFP copy number per cell were measured by qPCR. Values represent mean ± SD. P Values were determined by one-way ANOVA. Compared with PBS, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Compared with AAV8, #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001. n = 3/group (i). ns not significant. n = 6/group (e, f, j). Source data are provided as a Source Data file.
Fig. 2 Testing transduction of AAV8 and AAVv128 capsid following subretinal injections. a OCT images showing retinal blebbing formed at the site of subretinal administration. Representative animal eyes were shown at post-injection of necropsy (1 μL volume, n = 6). b Fluorescence fundoscopy of mouse eyes treated with PBS (1 μL volume, n = 6, scale bar: 500 μm). c–f Fluorescence fundoscopy of mouse eyes treated with ssAAV-CBA-eGFP vectors packaged with AAV8 (c) or AAVv128 (d) capsids (1×109 vg/eye, 1 μL volume, n = 6, scale bar: 500 μm). Mice were imaged at D14 and D28 post-injection, and each image of pixel intensity and mean pixel intensity per pixel area was quantified by using Image J (e, f). g, i Mice where sacrificed at D28 and eyes were harvested. Flat mounts of the retina were prepared and imaged by fluorescence microscopy to visualize native eGFP expression (g) and quantify by pixel intensity and mean pixel intensity per pixel area (i). Scale bar: 500 μm. h, j Mice retinal tissues were isolated and the relative eGFP copy number per cell were measured by qPCR. Values represent mean ± SD. P Values were determined by one-way ANOVA. Compared with PBS, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Compared with AAV8, #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001. n = 3/group (i). ns not significant. n = 6/group (e, f, j). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 Cross-section and immunofluorescence analyses of mice retina treated with subretinal injection of AAV8 and AAVv128 capsids. a Coronal sections of mice retina transduced with rAAV-CBA-eGFP. Native eGFP expression (green) shows the positively transduced cell. Scale bar: 200 μm. We conducted four repetitions for each sample, with each assay being operated independently. b IF stained sections (red) with antibodies against Rhodopsin (photoreceptors, Rod), Peanut agglutinin (PNA, photoreceptors, Cone), RPE65 (RPE cells), GS (Müller cells), GFAP (astrocytes), RBPMS (ganglion cells), PROX1 (anaplastic cells and ganglion cells) and Calbindin D28K (horizontal cells, anaplastic cells and ganglion cells) indicate the distribution of cell types across the retina. Native eGFP expression (green) that colocalize with IF staining (yellow or white) reveals the positively transduced cell type indicated. Scale bars: 20 μm (right column) or 200 μm (left column). INL inner nuclear layer, ONL outer nuclear layer. We conducted four repetitions for each sample, with each assay being operated independently.
Fig. 3 Cross-section and immunofluorescence analyses of mice retina treated with subretinal injection of AAV8 and AAVv128 capsids. a Coronal sections of mice retina transduced with rAAV-CBA-eGFP. Native eGFP expression (green) shows the positively transduced cell. Scale bar: 200 μm. We conducted four repetitions for each sample, with each assay being operated independently. b IF stained sections (red) with antibodies against Rhodopsin (photoreceptors, Rod), Peanut agglutinin (PNA, photoreceptors, Cone), RPE65 (RPE cells), GS (Müller cells), GFAP (astrocytes), RBPMS (ganglion cells), PROX1 (anaplastic cells and ganglion cells) and Calbindin D28K (horizontal cells, anaplastic cells and ganglion cells) indicate the distribution of cell types across the retina. Native eGFP expression (green) that colocalize with IF staining (yellow or white) reveals the positively transduced cell type indicated. Scale bars: 20 μm (right column) or 200 μm (left column). INL inner nuclear layer, ONL outer nuclear layer. We conducted four repetitions for each sample, with each assay being operated independently.CC BY · PubMed Central
Fig. 4 Biochemical and physiological properties analyses of AAVv128 and AAV8. a Heatmap displays of differential scanning fluorimetry (DSF) analyses used a 473 nm laser to excite SYBR Gold bound to DNA (vector genome extrusion) at pHs 6, 7 and 8. Color scaling depicted represent relative peak signals from highest to lowest value (brightest to dimmest, respectively). b The isoelectric point of AAV8 and AAVv128 were detected using capillary isoelectric focusing (cIEF). c The infectivity of AAV8 and AAVv128 were detected by a 96-well TCID50 format and quantitative polymerase chain reaction (qPCR). The relative anti-VEGF protein expression levels of AAV8 and AAVv128 on ARPE19 (e), HeLaRC32 (d) and HEK293 (f) cells were detected by ELISA, respectively. Values represent mean ± SD. P Values were determined by a two-tailed Student t Test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns not significant. n = 3/group. Source data are provided as a Source Data file.
Fig. 4 Biochemical and physiological properties analyses of AAVv128 and AAV8. a Heatmap displays of differential scanning fluorimetry (DSF) analyses used a 473 nm laser to excite SYBR Gold bound to DNA (vector genome extrusion) at pHs 6, 7 and 8. Color scaling depicted represent relative peak signals from highest to lowest value (brightest to dimmest, respectively). b The isoelectric point of AAV8 and AAVv128 were detected using capillary isoelectric focusing (cIEF). c The infectivity of AAV8 and AAVv128 were detected by a 96-well TCID50 format and quantitative polymerase chain reaction (qPCR). The relative anti-VEGF protein expression levels of AAV8 and AAVv128 on ARPE19 (e), HeLaRC32 (d) and HEK293 (f) cells were detected by ELISA, respectively. Values represent mean ± SD. P Values were determined by a two-tailed Student t Test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns not significant. n = 3/group. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 Assessing the performance of the AAVv128 and AAV8 during trafficking steps. a Schematic diagram for studying the effect of AAV8 Nab-positive monkey serum on AAVv128. b Neutralizing antibody (Nab) assay for the determination of the AAVv128 could escape positive-AAV8 Nab recongnition. c Depicting the process of the AAVv128 and AAV8 during trafficking steps. d, e, f, g, h, i, j, k The AAV binding (d, f), cellular uptake (e, g), nuclear uptake (h, i) and expression (j, k) of AAV8 and AAVv128 were detected by qPCR and ELISA, respectively. Values represent mean ± SD. P Values were determined by a two-tailed Student t Test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. n = 5/group (d, e, f, g, h, i), n = 3/group (j, k). Source data are provided as a Source Data file.
Fig. 5 Assessing the performance of the AAVv128 and AAV8 during trafficking steps. a Schematic diagram for studying the effect of AAV8 Nab-positive monkey serum on AAVv128. b Neutralizing antibody (Nab) assay for the determination of the AAVv128 could escape positive-AAV8 Nab recongnition. c Depicting the process of the AAVv128 and AAV8 during trafficking steps. d, e, f, g, h, i, j, k The AAV binding (d, f), cellular uptake (e, g), nuclear uptake (h, i) and expression (j, k) of AAV8 and AAVv128 were detected by qPCR and ELISA, respectively. Values represent mean ± SD. P Values were determined by a two-tailed Student t Test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. n = 5/group (d, e, f, g, h, i), n = 3/group (j, k). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 Cryo-EM reveals differences between AAVv128 and AAV8. a The rendered images of the empty AAVv128 was shown and labeled with the particle dimensions. Depth cueing with colors was used to indicate radius (<100 Å, blue; 100–120 Å, from cyan to green; > 140 Å, red). b Comparison of the capsid surfaces of AAV8 and AAVv128. Gray surface representation of the AAV8 (PDB, 6V12) and AAVv128 (PDB, 8JRE) generated from 60 VP monomers. The amino acid differences between with AAV8 and AAVv128 on the capsid surface were colored red. c The Structural superposition of AAV8 and AAVv128 VP shown as ribbon diagrams. The conserved β-barrel core motif and the αA helix were indicated, the positions of VR-I to VR-IX were labeled. d The residues in a featured fragment from AAVv128 VP3 VIII variable region (D584-N604) were shown as colored sticks and cartoon surrounded by density. e, f The residues of main difference between AAV8 (f) and AAVv128 (e) lied in the VP3 VIII variable region were shown as colored sticks. The residues that the insertion and the ‘pocket loop’ were labeled in a resplendent shade of red. g The identical or conserved residues were shown as letters with red or yellow backgrounds, while the non-conserved residues have a white background. The variable regions between different AAV serotypes were shown in cyan.
Fig. 6 Cryo-EM reveals differences between AAVv128 and AAV8. a The rendered images of the empty AAVv128 was shown and labeled with the particle dimensions. Depth cueing with colors was used to indicate radius (<100 Å, blue; 100–120 Å, from cyan to green; > 140 Å, red). b Comparison of the capsid surfaces of AAV8 and AAVv128. Gray surface representation of the AAV8 (PDB, 6V12) and AAVv128 (PDB, 8JRE) generated from 60 VP monomers. The amino acid differences between with AAV8 and AAVv128 on the capsid surface were colored red. c The Structural superposition of AAV8 and AAVv128 VP shown as ribbon diagrams. The conserved β-barrel core motif and the αA helix were indicated, the positions of VR-I to VR-IX were labeled. d The residues in a featured fragment from AAVv128 VP3 VIII variable region (D584-N604) were shown as colored sticks and cartoon surrounded by density. e, f The residues of main difference between AAV8 (f) and AAVv128 (e) lied in the VP3 VIII variable region were shown as colored sticks. The residues that the insertion and the ‘pocket loop’ were labeled in a resplendent shade of red. g The identical or conserved residues were shown as letters with red or yellow backgrounds, while the non-conserved residues have a white background. The variable regions between different AAV serotypes were shown in cyan.CC BY · PubMed Central
Fig. 7 Intraocular injections in large animals to evaluate the transduction efficacy of AAV8 and AAVv128. The New Zealand rabbit eyes treated by intravitreal injections or suprachoroidal injections of the AAV8 and AAVv128 confers detectable mCherry expression at days 28 post-injection (1 × 1011 vg/eye, 100 μL volume, n = 4). a, c Immunofluorescence analysis of the New Zealand rabbit retinas after intravitreal injection (a) and suprachoroidal injection (c). b, d The retina-choroid tissues of the New Zealand rabbit retinas after intravitreal injection (b) and suprachoroidal injection (d) were isolated and their viral genomic DNA content were measured by qPCR (n = 4). Scale bars: 50 μm (down column) or 2 mm (up column). e Infrared imaging analysis of suprachoroidal injections in cynomolgus monkeys. NHPs eyes treated by suprachoroidal injection of the AAV8 and AAVv128 capsid confers detectable eGFP expression at days 14 post-injection (3.5×1012 vg/eye, 100 μL volume, n = 1). f Transduction validation of NHPs eyes treated with AAV8 and AAVv128 by Scanning laser ophthalmoscopy (SLO); scale bars: 200 μm. GCL ganglion cell layer, INL inner nuclear layer, ONL outer nuclear layer. Values represent mean ± SD. P values were determined by a two-tailed Student t Test. #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001. Source data are provided as a Source Data file.
Fig. 7 Intraocular injections in large animals to evaluate the transduction efficacy of AAV8 and AAVv128. The New Zealand rabbit eyes treated by intravitreal injections or suprachoroidal injections of the AAV8 and AAVv128 confers detectable mCherry expression at days 28 post-injection (1 × 1011 vg/eye, 100 μL volume, n = 4). a, c Immunofluorescence analysis of the New Zealand rabbit retinas after intravitreal injection (a) and suprachoroidal injection (c). b, d The retina-choroid tissues of the New Zealand rabbit retinas after intravitreal injection (b) and suprachoroidal injection (d) were isolated and their viral genomic DNA content were measured by qPCR (n = 4). Scale bars: 50 μm (down column) or 2 mm (up column). e Infrared imaging analysis of suprachoroidal injections in cynomolgus monkeys. NHPs eyes treated by suprachoroidal injection of the AAV8 and AAVv128 capsid confers detectable eGFP expression at days 14 post-injection (3.5×1012 vg/eye, 100 μL volume, n = 1). f Transduction validation of NHPs eyes treated with AAV8 and AAVv128 by Scanning laser ophthalmoscopy (SLO); scale bars: 200 μm. GCL ganglion cell layer, INL inner nuclear layer, ONL outer nuclear layer. Values represent mean ± SD. P values were determined by a two-tailed Student t Test. #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 8 Laser-induced CNV model in NHPs are used to evaluate the efficacy of nAMD by AAVv128-anti-VEGF vector. a The anti-VEGF protein levels of monkey treated with suprachoroidal injection of AAV8-anti-VEGF vector and AAVv128-anti-VEGF vector (1×1012 vg/eye, 100 μL volume, n = 1) were measured at Day 56. AAV8-anti-VEGF vector and AAVv128-anti-VEGF vector were injected into suprachoroidal space at Day0, six laser spots were applied around the macula of each eye using laser at 28-days. The NHPs were sacrificed at Day 56 (after induction of choroidal neovascularization by Laser-induced CNV model) and eyes were harvested. The retinal tissues of the NHP retinas after suprachoroidal injection were isolated and the anti-VEGF protein expression level of AAV8-treated group and AAVv128-treated group were measured by ELISA. b Timeline of studying AAV-anti-VEGF vector to evaluate the efficacy of nAMD by using Laser-induced CNV model in NHP eyes. c, d Fluorescein fundus angiograph (FFA) was used to determine the number of Grade IV lesions. Representative FFA of NHP eyes treated with suprachoroidal injection of Vehicle, AAV8-anti-VEGF vector and AAVv128-anti VEGF vector at 35-days (c) and 49-days (d) (2×1012 vg/eye, 100 μL volume, n = 8). e Percentage of Grade IV lesions with suprachoroidal injection of Vehicle (formulation buffer), AAV8-anti-VEGF vector and AAVv128-anti-VEGF vector. Numbers on the top of bars show the number of Grade IV lesions scored over the total number of assessable lesions (six laser spots/eye, n = 8). OD oculus dextrus, OS oculus sinister, FFA fundus fluorescence angiography. Values represent mean ± SD. P values were determined by one-way ANOVA. Compared with vehicle, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Compared with AAV8, #P < 0.05, ##P < 0.01 (P = 0.0074). n = 8/group. Source data are provided as a Source Data file.
Fig. 8 Laser-induced CNV model in NHPs are used to evaluate the efficacy of nAMD by AAVv128-anti-VEGF vector. a The anti-VEGF protein levels of monkey treated with suprachoroidal injection of AAV8-anti-VEGF vector and AAVv128-anti-VEGF vector (1×1012 vg/eye, 100 μL volume, n = 1) were measured at Day 56. AAV8-anti-VEGF vector and AAVv128-anti-VEGF vector were injected into suprachoroidal space at Day0, six laser spots were applied around the macula of each eye using laser at 28-days. The NHPs were sacrificed at Day 56 (after induction of choroidal neovascularization by Laser-induced CNV model) and eyes were harvested. The retinal tissues of the NHP retinas after suprachoroidal injection were isolated and the anti-VEGF protein expression level of AAV8-treated group and AAVv128-treated group were measured by ELISA. b Timeline of studying AAV-anti-VEGF vector to evaluate the efficacy of nAMD by using Laser-induced CNV model in NHP eyes. c, d Fluorescein fundus angiograph (FFA) was used to determine the number of Grade IV lesions. Representative FFA of NHP eyes treated with suprachoroidal injection of Vehicle, AAV8-anti-VEGF vector and AAVv128-anti VEGF vector at 35-days (c) and 49-days (d) (2×1012 vg/eye, 100 μL volume, n = 8). e Percentage of Grade IV lesions with suprachoroidal injection of Vehicle (formulation buffer), AAV8-anti-VEGF vector and AAVv128-anti-VEGF vector. Numbers on the top of bars show the number of Grade IV lesions scored over the total number of assessable lesions (six laser spots/eye, n = 8). OD oculus dextrus, OS oculus sinister, FFA fundus fluorescence angiography. Values represent mean ± SD. P values were determined by one-way ANOVA. Compared with vehicle, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Compared with AAV8, #P < 0.05, ##P < 0.01 (P = 0.0074). n = 8/group. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 1 Not valid · 22 Not checked · 101 Own results and interpretations

56 more claims

Create a free account to see all 128 claims and to verify the 32 references still open.

See all claims — free account
  • Probably not a substantial claim. 29
  • It may state two separate claims as one. 45
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 93 references

Cited by

See all 39

Metadata

Authors
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., Ke, X., Zheng, Q., & Sun, X.
Affiliations
  • Sichuan University (CN)
  • Guangzhou Laboratory (CN)
Corresponding author
  • Ke, Xiao
  • Zheng, Qiang
  • Sun, Xun
Venue
Nature Communications
Published
2024-05-06
Volume
15
Issue
1
Pages
3780-3780
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4396673495
Cited by
39
References
93
Citations by year
2026: 11 · 2025: 18 · 2024: 10
FWCI
10.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
the Fundamental Research Funds for the Central Universities
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
adeno-associated virus, ocular gene delivery, suprachoroidal injection, retinal transduction, photoreceptors, retinal pigment epithelium, choroidal neovascularization, neovascular age-related macular degeneration, anti-VEGF therapy, non-human primates, cryo-EM structure, endosomal escape, nuclear uptake, retinal gene therapy
MeSH terms
Dependovirus, Animals, Disease Models, Animal, Genetic Vectors, Humans, Macular Degeneration, Male, Mice, Inbred C57BL, Rabbits, Retina, Transduction, Genetic, Genetic Therapy, Gene Transfer Techniques, Choroidal Neovascularization, Capsid Proteins, Vascular Endothelial Growth Factor A, Mice, Retinal Pigment Epithelium, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species. https://app.cochat.ai/papers/10.1038/s41467-024-48221-4
The paper
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., Ke, X., Zheng, Q., & Sun, X. (2024). An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species. Nature Communications. https://doi.org/10.1038/s41467-024-48221-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.